The Effectiveness of Course Therapy with Actovegin of Minimal Cognitive Dysfunction in 1st-Degree Relatives of Patients with Alzheimer’s Disease: the Role of ApoE Genotype

The aim of the study: evaluation of the impact of long-term effects of repeated courses of Actovegin therapy on indicators of minimal cognitive dysfunction (MCD) in relatives of patients with Alzheimer’s disease (AD).

Study participant: 76 people with signs of minimal cognitive dysfunction objectively confirmed by clinical and neuropsychological examination, who are relatives of the 1st degree of relatives of patients with AD.

Study design: a prospective comparative study of the effects of repeated courses (4 courses in total) of three-month oral therapy with Actovegin (at a daily dose of 600 mg divided into three doses of 200 mg) every 1.5 years in groups of relatives with ApoE4(+) and ApoE4(–) genotypes.

Methods: psychometric, neuropsychological, molecular genetic, statistical.

Results: in the study, the effectiveness of 4 repeated courses of Actovegin therapy in relatives with manifestations of MСD was established. According to the CGI-I subscale, no deterioration was found over a period of 4 years and 9 months. By the end of the study, in 86.9% of all cases, a pronounced and moderate improvement was achieved.

Conclusion: minimal cognitive dysfunction in first-degree relatives of AD patients, both in carriers of the ApoE4(–) genotype and especially in carriers of the ApoE4(+) genotype, is the basis for special attention to measures to prevent cognitive deficits.

1. Leduc V, Jasmin-Bélanger S, Poirier J. APOE and cholesterol homeostasis in Alzheimer’s disease. Trends Mol Med. 2010;16(10):469–477. doi: 10.1016/j.molmed.2010.07.008 PMID: 20817608.

2. Wahrle SE, Jiang H, Parsadanian M, Hartman RE, Bales KR, Paul SM, Holtzman DM. Deletion of Abca1 increases Abeta deposition in the PDAPP transgenic mouse model of Alzheimer disease. J Biol Chem. 2005;280(52):43236-42. doi: 10.1074/jbc.M508780200 Epub 2005 Oct 5. PMID: 16207708.

3. Rebeck GW. The role of APOE on lipid homeostasis and in ammation in normal brains. J Lipid Res. 2017;58(8):1493–1499. doi: 10.1194/jlr.R075408 Epub 2017 Mar 2. PMID: 28258087; PMCID: PMC5538293.

4. Jarvik LF, Brazer D. Children of Alzheimer parents: An Overview. J Geriatr Psychiatry Neurol. 2005;18(4):181–186. doi: 10.1177/0891988705281859

5. Small GW, Okonek A, Mandelkern MA, La Rue A. Age-associated memory loss: initial neuropsychological and cerebral metabolic  ndings of a longitudinal study. Int Psychogeriatr.1994;6(1):23–44. doi: 10.1017/s1041610294001596

6. Sager MA, Hermann B, La Rue A. Middle-aged children of persons with Alzheimer’s disease: APOE genotypes and cognitive function in the Wisconsin Registry for Alzheimer’s Prevention. J Geriatr Psychiatry Neurol. 2005;18(4):245–249. doi: 10.1177/0891988705281882

7. Selezneva ND, Roshchina IF. A comprehensive follow-up clinical and psychological study of cognitive features of mental activity in relatives of the  rst degree of relationship of patients with Alzheimer’s disease. Psychiatry (Moscow) (Psikhiatriya). 2017;(4):27–36. (In Russ.).

8. Chikina ES, Mednikov OI, Belousov YuB. Pharmacoeconomic aspects of treatment of dementia in the Russian Federation. RMJ. 2005;(20):1354–1360. (In Russ.).

9. Prince M, Wimo A, Guerchet M, Ali GC, Wu YT, Prina M. The Global Impact of Dementia: An analysis of prevalence, incidence, cost and trends. In: World Alzheimer Report 2015, Alzheimer’s Disease International. London:1–23.

10. Breitner JC. Clinical genetics and genetic counseling in Alzheimer disease. Ann Intern Med. 1991;115(8):601–616. doi: 10.7326/0003-4819-601 PMID: 1892331.

11. Buchmayer F, Pleiner J, Elmlinger MW, Lauer G, Nell G, Sitte HH. Actovegin®: a biological drug for more than 5 decades. Wien Med Wochenschr. 2011;161(3–4):80–88.

12. Zhao WQ, Chen H, Quon MJ, Alkon DL. Insulin and the insulin receptor in experimental models of learning and memory. Eur J Pharmacol. 2004;490(1–3):71–81.

13. Elmlinger MW, Kriebel M, Ziegler D. Neuroprotective and anti-oxidative effects of the hemodialysate actovegin on primary rat neurons in vitro. Neuromolecular Med. 2011;13(4):266–274.

14. Millucci L, Raggiaschi R, Franceschini D, Terstappen G, Santucci A. Rapid aggregation and assembly in aqueous solution of A beta (25–35) peptide. J Biosci. 2009;34(2):293–303. doi: 10.1007/s12038-009-0033-3

15. Klementiev B, Novikova T, Novitskaya V, Walmod PS, Dmytriyeva O, Pakkenberg B, Berezin V, Bock E. A neural cell adhesion molecule-derived peptide reduces neuropathological signs and cognitive impairment induced by Abeta25–35. Neuroscience. 2007;145(1):209–224. doi: 10.1016/j.neuroscience.2006.11.060

16. Mikhaylova NM, Selezneva ND, Kalyn IaB, Roshchina IF, Gavrilova SI. Ef cacy of actovegin in the treatment of elderly patients with vascular mild cognitive impairment. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2013;113(7–2):69–76. (In Russ.).

17. Seleznеva ND, Kolykhalov IV, Gavrilova SI. A Comparative Prospective Multidisciplinary Research of Efficiency of Choline Alphoscerate in Prevention of Cognitive De ciency Progressing in Relatives of Patients with Alzheimer’s Disease. Psychiatry (Moscow) (Psikhiatriya). 2020;18(1):6–15. (In Russ.). doi: 10.30629/2618-6667-2020-18-1-6-15

18. Korovaytseva GI, Chipped TV, Selezneva ND, Gavrilova SI, Golimbet VE, Voskresenskaya NI, Rogayev EI. Genetic association between alleles of a gene of E (APOE) apolipoprotein and various forms of Alzheimer’s disease. Genetics. 2001;37(4):529–533. (In Russ.).

19. Korsakova NK, Balashova EYu, Roshchina IF. Express-method for assessing cognitive functions in normal aging. Zhurnal Nevrologii i Psihiatrii imeni S.S. Korsakova. 2009;109(2):44–50. (In Russ.)

20. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU Side Effect Rating Scale. Comprehensive Rating Scale for Psychotropic Drugs and a Cross-Sectional Study of Side Effects in Neuroleptic-Treated Patients. Acta Psychiatr Scand Suppl. 1987;334:1– 100. doi:10.1111/j.1600-0447.1987.tb10566

21. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999;56:303–308. doi: 10.1001/archneur.56.3.303

22. Selezneva ND, Gavrilova SI, Kolykhalov IV. Delayed effects of cerebrolysin in the prevention of cognitive impairment progression in the  rst degree relatives of patients with Alzheimer’s disease: the role of the ApoE genotype. S.S. Korsakov Journal of Neurology and Psychiatry/Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2020;120(10, vyp. 2):32–39. (In Russ.). doi: 10.17116/jnevro202112110232

23. Selezneva ND, Gavrilova SI, Roshchina IF, Ponomareva EV. Citicoline in the treatment of cognitive impairment in  rst-degree relatives of AD patients: the in uence of the ApoE genotype. S.S. Korsakov Journal of Neurology and Psychiatry/Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2021;121(10, vyp. 2):30– 36. (In Russ.). doi: 10.17116/jnevro202112110230

24. Seleznеva ND, Gavrilova SI, Ponomareva EV. Ef cacy and Safety of Citicoline to Prevent Cognitive De ciency Progression in First-Degree Relatives of Patients with Alzheimer’s Disease: Prospective Study. Psychiatry (Moscow) (Psikhiatriya). 2020;18(4):33–40. (In Russ.). doi: 10.30629/2618-6667-2020-18-4-3340

25. Selezneva ND, Roshchina IF, Ponomareva EV, Gavrilova SI. Citicoline in the treatment of mild cognitive impairment in blood relatives of patients with Alzheimer’s disease: immediate and long-term effects of course therapy. Psychiatry (Moscow) (Psikhiatriya). 2021;19(4):42–51. (In Russ.). doi: 10.30629/26186667-2021-19-4-42-51